NO178187C - Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser

Info

Publication number
NO178187C
NO178187C NO910016A NO910016A NO178187C NO 178187 C NO178187 C NO 178187C NO 910016 A NO910016 A NO 910016A NO 910016 A NO910016 A NO 910016A NO 178187 C NO178187 C NO 178187C
Authority
NO
Norway
Prior art keywords
preparation
therapeutically active
containing heterocyclic
heterocyclic compounds
analogous process
Prior art date
Application number
NO910016A
Other languages
English (en)
Norwegian (no)
Other versions
NO910016D0 (no
NO178187B (no
NO910016L (no
Inventor
Manoj C Desai
Terry J Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO910016D0 publication Critical patent/NO910016D0/no
Publication of NO910016L publication Critical patent/NO910016L/no
Publication of NO178187B publication Critical patent/NO178187B/no
Publication of NO178187C publication Critical patent/NO178187C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO910016A 1990-01-04 1991-01-03 Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser NO178187C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1990/000116 WO1991009844A1 (en) 1990-01-04 1990-01-04 Substance p antagonists

Publications (4)

Publication Number Publication Date
NO910016D0 NO910016D0 (no) 1991-01-03
NO910016L NO910016L (no) 1991-07-05
NO178187B NO178187B (no) 1995-10-30
NO178187C true NO178187C (no) 1996-02-07

Family

ID=22220614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO910016A NO178187C (no) 1990-01-04 1991-01-03 Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser

Country Status (27)

Country Link
EP (2) EP0558156A3 (es)
JP (1) JPH0757748B2 (es)
KR (1) KR930009441B1 (es)
CN (2) CN1035944C (es)
AT (1) ATE115127T1 (es)
AU (1) AU625511B2 (es)
BR (1) BR9100016A (es)
CA (1) CA2033497C (es)
CZ (1) CZ289485B6 (es)
DE (1) DE69014848T2 (es)
DK (1) DK0436334T3 (es)
ES (1) ES2064667T3 (es)
FI (2) FI114096B (es)
GR (1) GR3014940T3 (es)
HU (5) HUT68130A (es)
IE (1) IE63770B1 (es)
IL (3) IL112348A (es)
MY (1) MY105438A (es)
NO (1) NO178187C (es)
NZ (1) NZ236581A (es)
PL (5) PL164244B1 (es)
PT (1) PT96405B (es)
RU (1) RU2105758C1 (es)
UA (1) UA41251C2 (es)
WO (1) WO1991009844A1 (es)
YU (1) YU48026B (es)
ZA (1) ZA9136B (es)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830863A (en) * 1988-06-20 1998-11-03 Merrell Pharmaceuticals Inc. Neurokinin A antagonists
US6218364B1 (en) 1988-06-20 2001-04-17 Scott L. Harbeson Fluorinated neurokinin A antagonists
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
KR0160142B1 (ko) * 1990-05-31 1998-12-01 알렌 제이. 스피겔 치환된 피페리딘의 제조방법
EP0532527B1 (en) * 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
DK0540526T3 (da) * 1990-07-23 1995-04-18 Pfizer Quinuclidinderivater
PL169993B1 (pl) * 1991-03-26 1996-09-30 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL PL
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
EP0589924B1 (en) * 1991-06-20 1996-09-04 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
TW202432B (es) * 1991-06-21 1993-03-21 Pfizer
CA2112397A1 (en) * 1991-08-20 1993-03-04 Raymond Baker Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
ATE195867T1 (de) * 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
EP0636130A1 (en) * 1992-04-15 1995-02-01 Merck Sharp & Dohme Ltd. Azacyclic compounds
PT641328E (pt) * 1992-05-18 2002-04-29 Pfizer Derivados aza-biciclicos em ponte como antagonistas da substancia p
US6048859A (en) * 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
ATE173725T1 (de) * 1992-07-28 1998-12-15 Merck Sharp & Dohme Azazyklische verbindungen
JPH07506379A (ja) * 1992-08-04 1995-07-13 ファイザー・インコーポレーテッド 物質ｐ受容体アンタゴニストとしての３−ベンジルアミノ−２−フェニル−ピペリジン
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
AU4973693A (en) * 1992-09-10 1994-03-29 Merck Sharp & Dohme Limited Alcohols and ethers with aromatic substituents as tachykinin-antagonists
GB9220286D0 (en) * 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
ATE194340T1 (de) * 1992-12-10 2000-07-15 Pfizer Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
US6369074B1 (en) * 1992-12-10 2002-04-09 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
GB9300051D0 (en) * 1993-01-04 1993-03-03 Merck Sharp & Dohme Therapeutic agents
JPH08506823A (ja) * 1993-02-18 1996-07-23 メルク シヤープ エンド ドーム リミテツド アザ環式化合物、該化合物を含む組成物及びタキキニン拮抗剤としての該化合物の使用
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
WO1994027966A1 (en) * 1993-05-28 1994-12-08 Pfizer Inc. Process for preparing and resolving 2-phenyl-3-aminopiperidine
US5348955A (en) * 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
GB9317104D0 (en) 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
DE69433744T2 (de) * 1993-09-17 2004-10-14 Pfizer Inc. 3-amino-5-carboxy-substituierte piperidine und 3-amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten
WO1995007908A1 (en) * 1993-09-17 1995-03-23 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
TW263498B (es) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
EP0741704A1 (en) * 1994-01-28 1996-11-13 MERCK SHARP & DOHME LTD. Aralkylamino substituted azacyclic therapeutic agents
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
GB9408872D0 (en) * 1994-05-03 1994-06-22 Zeneca Ltd Heterocyclic compounds
GB9418545D0 (en) * 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
DE69534213T2 (de) * 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2729952B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
DK0780375T3 (da) 1995-12-21 2002-10-07 Pfizer 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister
AU2462097A (en) * 1996-10-04 1998-04-24 Alcon Laboratories, Inc. The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
CA2287487A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating eating disorders
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
AU738047B2 (en) * 1997-08-04 2001-09-06 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating mania
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
BR9913201A (pt) * 1998-08-25 2001-05-08 Novartis Ag Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CZ20023168A3 (cs) 2000-03-21 2003-02-12 Smithkline Beecham Corporation Inhibitory proteázy
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
WO2002028853A1 (en) * 2000-10-02 2002-04-11 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
US6709651B2 (en) 2001-07-03 2004-03-23 B.M.R.A. Corporation B.V. Treatment of substance P-related disorders
EP1460062A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical NITROGEN-CONTAINING CYCLIC KETONE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
US7220098B2 (en) 2003-05-27 2007-05-22 General Electric Company Wear resistant variable stator vane assemblies
US20060063766A1 (en) 2004-07-15 2006-03-23 Molino Bruce F Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin
ATE452130T1 (de) 2004-10-18 2010-01-15 Lilly Co Eli 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
US7543992B2 (en) 2005-04-28 2009-06-09 General Electric Company High temperature rod end bearings
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP3536690A1 (en) 2007-01-10 2019-09-11 MSD Italia S.r.l. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
MX2011007272A (es) * 2009-01-27 2011-08-08 Hoffmann La Roche Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1.
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2925888B1 (en) 2012-11-28 2017-10-25 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
ES2980110T3 (es) * 2018-02-26 2024-09-30 Ospedale San Raffaele Srl Antagonistas de NK-1 para uso en el tratamiento del dolor ocular
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL89969C (es) * 1954-02-05
GB1060160A (en) * 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US3992389A (en) * 1970-09-03 1976-11-16 John Wyeth & Brother Limited Heterocyclic compounds
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
KR0160142B1 (ko) * 1990-05-31 1998-12-01 알렌 제이. 스피겔 치환된 피페리딘의 제조방법

Also Published As

Publication number Publication date
MY105438A (en) 1994-10-31
EP0436334A2 (en) 1991-07-10
FI910034A0 (fi) 1991-01-03
EP0436334A3 (en) 1992-05-27
PL293392A1 (en) 1992-07-13
ATE115127T1 (de) 1994-12-15
AU625511B2 (en) 1992-07-16
CA2033497A1 (en) 1991-07-05
EP0436334B1 (en) 1994-12-07
HUT68180A (en) 1995-05-29
NO910016D0 (no) 1991-01-03
PL293391A1 (en) 1992-07-13
CZ289485B6 (cs) 2002-02-13
CN1087083A (zh) 1994-05-25
DK0436334T3 (da) 1995-02-13
PL164205B1 (en) 1994-06-30
FI910034L (fi) 1991-07-05
HUT68179A (en) 1995-05-29
KR910014350A (ko) 1991-08-31
DE69014848D1 (de) 1995-01-19
JPH0757748B2 (ja) 1995-06-21
PL164204B1 (pl) 1994-06-30
EP0558156A3 (en) 1993-10-06
ES2064667T3 (es) 1995-02-01
NO178187B (no) 1995-10-30
PL293389A1 (en) 1992-07-13
CN1045595C (zh) 1999-10-13
HU220602B1 (hu) 2002-03-28
CS1091A3 (en) 1991-08-13
WO1991009844A1 (en) 1991-07-11
CA2033497C (en) 1997-01-07
IE910007A1 (en) 1991-07-17
KR930009441B1 (ko) 1993-10-04
EP0558156A2 (en) 1993-09-01
FI114096B (fi) 2004-08-13
UA41251C2 (uk) 2001-09-17
NO910016L (no) 1991-07-05
PL164244B1 (en) 1994-07-29
PL163967B1 (pl) 1994-06-30
YU48026B (sh) 1996-10-09
PL293390A1 (en) 1992-07-13
CN1053060A (zh) 1991-07-17
GR3014940T3 (en) 1995-05-31
IL112348A (en) 1998-06-15
NZ236581A (en) 1992-10-28
PT96405B (pt) 1998-06-30
IL96821A0 (en) 1991-09-16
HUT68130A (en) 1995-05-29
HUT60719A (en) 1992-10-28
RU2105758C1 (ru) 1998-02-27
HU910006D0 (en) 1991-08-28
BR9100016A (pt) 1991-10-22
ZA9136B (en) 1992-08-26
IE63770B1 (en) 1995-06-14
PL164203B1 (pl) 1994-06-30
YU491A (sh) 1994-01-20
AU6862191A (en) 1991-07-18
PL288592A1 (en) 1992-06-15
FI20040479A7 (fi) 2004-04-01
HU222724B1 (hu) 2003-09-29
IL96821A (en) 1997-03-18
IL112348A0 (en) 1995-03-30
JPH04103570A (ja) 1992-04-06
PT96405A (pt) 1991-10-15
CN1035944C (zh) 1997-09-24
DE69014848T2 (de) 1995-05-04

Similar Documents

Publication Publication Date Title
NO178187C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser
NO934470L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive, mett ede, heterocykliske carboxamidderivater
FI905941A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten 2-asyyliaminotiatsolijohdannaisten valmistamiseksi
FI892787L (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1-indolyylialkyyli-4-(substituoitu pyridinyyli)piperatsiinien valmistamiseksi
NO179283C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte azoler
NO178068C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive tiazolidindionderivater
FI894604L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyridyyli- ja pyrimidyylipiperatsiinijohdannaisten valmistamiseksi
NO175976C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-(1,6-dihydro-6-okso-pyridazinyl-3-oksy)-3-kromanolderivater
PH25106A (en) 1-acyl-3-(4-(2-pyrimidinyl)-1-piperazinyl) propanes, pharmaceutical composition containing said compound and method of use thereof
FI906084L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 5-(2-metyyli-4,4,4-trifluoributyylikarbamoyyli)indolijohdannaisten valmistamiseksi
HUT46507A (en) Insecticidal composition comprising 5-member heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazine compounds and process for producing such compounds
GB2247237B (en) 1-(N'-Cyanoguanyl) derivatives of N-containing five-membered ring heterocycles
FI880282L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3-aryyli-5-alkyylisulfinyyli- ja sulfonyyli-4H-1,2,4-triatsolien valmistamiseksi
FI894812A0 (fi) Menetelmä valmistaa farmakologisesti arvokkaita 2-karbonyylisubstituoituja N,N'-di(trimetoksibentsoyyli)piperatsiineja
FI893121L (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
FI915518A7 (fi) Menetelmä lääkinnällisesti vaikuttavien heterosyklisesti substituoitujen piperatsinoalkyylibentsoksatsiini- ja -tiatsiiniyhdisteiden valmistamiseksi
FI97388B (fi) Menetelmä heterosyklisten NMDA-antagonistien valmistamiseksi
FI912733L (fi) Menetelmä terapeuttisesti käyttökelpoisten /(1-aryylipyrrolidin-2-yyli)metyyli/piperatsiinijohdannaisten valmistamiseksi
NO954076L (no) Fremgangsmåte for fremstilling av en krystallform og et farmasöytisk preparat derav
NO174419C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive heterocykliske forbindelser